Director at Globus Medical (GMED) gets 15,000 stock options

Rhea-AI Filing Summary

Globus Medical director Dan Lemaitre received a new stock option grant. On January 21, 2026, he was awarded options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share, with no cost reported for the options themselves. These options will vest on January 1, 2027 and expire on January 21, 2036. Following this grant, Lemaitre beneficially owns 15,000 derivative securities directly through this option award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lemaitre Dan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy Class A Common Stock)	15,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 15,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lemaitre Dan

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$94.15	01/21/2026		A		15,000		(1)	01/21/2036	Class A Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. These options were granted on January 21, 2026, and will vest on January 1, 2027.

	/s/ Kelly G. Huller, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Dan Lemaitre report for GMED?

Dan Lemaitre, a director of Globus Medical (GMED), reported receiving a grant of stock options on January 21, 2026, rather than buying or selling existing shares.

How many stock options were granted to Dan Lemaitre at Globus Medical (GMED)?

Dan Lemaitre was granted 15,000 stock options, each representing the right to buy one share of Globus Medical Class A common stock.

What is the exercise price of Dan Lemaitre’s Globus Medical stock options?

The stock options granted to Dan Lemaitre have an exercise price of $94.15 per share for Globus Medical Class A common stock.

When do Dan Lemaitre’s stock options in Globus Medical vest and expire?

The options granted to Dan Lemaitre were granted on January 21, 2026, will vest on January 1, 2027, and will expire on January 21, 2036.

How many Globus Medical derivative securities does Dan Lemaitre own after this transaction?

After the reported transaction, Dan Lemaitre beneficially owns 15,000 derivative securities in the form of stock options, held directly.

Did Dan Lemaitre pay anything for the Globus Medical options at the time of grant?

The filing lists a price of $0 for the derivative security, indicating no cash consideration was paid at the time of the stock option grant.